Targeting the p53 Pathway in CAR-T Cell Engineering via Adenine Base Editing: A Safer Strategy for Cancer Immunotherapy

Rezaei, S. & Ranjbar, S. (2024). Targeting the p53 Pathway in CAR-T Cell Engineering via Adenine Base Editing: A Safer Strategy for Cancer Immunotherapy. (e739552). Iranian Biomedical Journal, 0(0), e739552 https://doi.org/10.61882/ibj.5351

Rezaei, S., & Ranjbar, S. "Targeting the p53 Pathway in CAR-T Cell Engineering via Adenine Base Editing: A Safer Strategy for Cancer Immunotherapy" .e739552 , Iranian Biomedical Journal, 0, 0, 2024, e739552. doi: 10.61882/ibj.5351

Rezaei S., Ranjbar S. (2024). 'Targeting the p53 Pathway in CAR-T Cell Engineering via Adenine Base Editing: A Safer Strategy for Cancer Immunotherapy', Iranian Biomedical Journal, 0(0), e739552. doi: 10.61882/ibj.5351

S. Rezaei & S. Ranjbar, "Targeting the p53 Pathway in CAR-T Cell Engineering via Adenine Base Editing: A Safer Strategy for Cancer Immunotherapy," Iranian Biomedical Journal, 0 0 (2024): e739552, doi: 10.61882/ibj.5351

Rezaei S., Ranjbar S. Targeting the p53 Pathway in CAR-T Cell Engineering via Adenine Base Editing: A Safer Strategy for Cancer Immunotherapy. Iranian Biomedical Journal. 2024;0(0):e739552. doi: 10.61882/ibj.5351